A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients

P Burbaud, L Wiart, J L Dubos, E Gaujard, X Debelleix, P A Joseph, J M Mazaux, B Bioulac, M Barat, A Lagueny, P Burbaud, L Wiart, J L Dubos, E Gaujard, X Debelleix, P A Joseph, J M Mazaux, B Bioulac, M Barat, A Lagueny

Abstract

Objective: To confirm the apparent effectiveness of botulinum toxin (BTX) in hemiparetic patients with ankle plantar flexors and foot invertor spasticity.

Methods: Twenty three hemiparetic patients with spasticity of the ankle plantar flexors and foot invertors were included in a randomised double blind, placebo controlled study with BTX. Patients were examined on days 0, 30, 90, and 120 and received one injection of BTX and one of placebo in a random order at day 0 and day 90.

Results: Patients reported a clear subjective improvement in foot spasticity after BTX (P = 0.0014) but not after placebo. Significant changes were noted in Ashworth scale values for ankle extensors (P < 0.0001) and invertors (P = 0.0002), and for active ankle dorsiflexion (P = 0.0001). Gait velocity was slightly but not significantly (P = 0.0731) improved after BTX injections. The severity of spasticity did not modify treatment efficacy, but BTX was less effective in patients with longer duration of spasticity (P = 0.0081).

Conclusion: The efficacy of BTX injections in the treatment of spastic foot suggests that BTX may be particularly useful during the first year after a stroke.

References

    1. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):232-5
    1. J Neurol Neurosurg Psychiatry. 1994 Nov;57(11):1321-4
    1. N Engl J Med. 1981 Jan 1;304(1):28-33
    1. N Engl J Med. 1981 Jan 8;304(2):96-9
    1. Phys Ther. 1987 Feb;67(2):206-7
    1. Int Disabil Stud. 1988;10(3):97-100
    1. N Engl J Med. 1989 Jun 8;320(23):1517-21
    1. Br J Clin Pract. 1989 Nov;43(11):401-3
    1. Neurosurgery. 1990 Feb;26(2):300-6
    1. Ann Neurol. 1990 Oct;28(4):512-5
    1. Brain. 1991 Feb;114 ( Pt 1A):233-44
    1. Rev Neurol (Paris). 1992;148(3):212-4
    1. J Neurol. 1992 Aug;239(7):375-8
    1. J Pediatr Orthop. 1993 Jul-Aug;13(4):489-95
    1. Nervenarzt. 1993 Aug;64(8):517-23
    1. Neurology. 1993 Sep;43(9):1715-8
    1. Am J Phys Med Rehabil. 1993 Dec;72(6):364-8
    1. Dev Med Child Neurol. 1994 May;36(5):379-85
    1. Mov Disord. 1994 Mar;9(2):213-7
    1. Scand J Rehabil Med. 1975;7(1):13-31

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren